NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NanoViricides Coverage Initiation and Lead Drug Candidate NV-387
NanoViricides received an 'Outperform' rating and $6 price target from Noble Capital Markets, highlighting its broad-spectrum antiviral candidate NV-387. The company also discussed its technology platform and regulatory progress in a fireside chat.
Noble Capital Markets initiated coverage with an 'Outperform' rating and a $6.00 price target.
Independent analyst Robert LeBoyer of Noble Capital Markets initiated the coverage.
The lead drug candidate is NV-387, a broad-spectrum antiviral targeting RSV, COVID, Long COVID, Influenza, MPOX/Smallpox, and Measles.
The company has received FDA Orphan Drug Designation and has filed for Rare Pediatric Disease Designation for measles.
NV-CoV-2 is a nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles.
The company licenses technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, established at its foundation in 2005.
The company is developing drugs for oral and genital Herpes, viral eye diseases (EKC, herpes keratitis), H1N1, H5N1, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.